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Abstract 
Background: Platelets are a critical element in coagulation and inflammation, and 
activated platelets are linked to cancer risk through diverse mechanisms. However, a 
causal relationship between platelets and risk of lung cancer remains unclear.  
Methods: We performed single and combined multiple instrumental variable 
Mendelian Randomization (MR) analysis by an inverse-weighted (IVW) method, in 
addition to a series of sensitivity analyses. Summary data for associations between 
single nucleotide polymorphisms (SNPs) and platelet count is from a recent 
publication including 48,666 Caucasian Europeans and International Lung Cancer 
Consortium and Transdisciplinary Research in Cancer of the Lung data consisting of 
29,266 cases and 56,450 controls analyze associations between candidate single 
nucleotide polymorphisms and lung cancer risk.  
Results: Multiple instrumental variable analysis incorporating six SNPs showed a 62% 
increased risk of overall NSCLC (OR, 1.62; 95%CI, 1.15–2.27; P = 0.005) and 200% 
increased risk for small cell lung cancer (OR, 3.00; 95%CI, 1.27–7.06; P = 0.01), 
respectively. Results showed only a trending association with NSCLC histological 
subtypes, which may be due to insufficient sample size and/or weak effect size. A 
series of sensitivity analysis retained these findings. 
 
Conclusion: Our findings suggest a causal relationship between elevated platelet 
count and increased risk of lung cancer and provide evidence of possible anti-platelet 
interventions for lung cancer prevention. 
 
Impact: Our ﬁndings suggest a causal relationship of increased platelet count and risk of 
lung cancer, which also provide a better understanding of lung cancer etiology and 
potential evidence for anti-platelet interventions for lung cancer prevention.  
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Lung cancer, a highly invasive, rapidly metastasizing cancer, has been the leading 
cause of cancer deaths worldwide for decades, accounting for more than one million 
deaths each year [1] . Smoking is a major risk factor for lung cancer and accounts for 
about 80% of male and 50% of female lung cancer cases [2]. In addition, 
environmental–occupational exposures [3, 4] , lifestyle, and genetic variants [5] have 
been broadly explored as risks/predisposing factors for lung cancer. However, 
aspects of lung cancer risk remain largely unexplained and thus warrant further study. 
 
The lung was recently noted to play a major role in platelet biogenesis and act as an 
ideal bioreactor for production of mature platelets from megakaryocytes, which 
account for ~50% of total platelet production [6] . Platelets are an important element in 
coagulation and inflammation, and diverse mechanisms link activated platelets to 
cancer progression [7, 8].  It has been identified that several variants in those 
chromosomal regions associated with platelet count (PLT) have associations with 
myocardial infraction, autoimmune and hematologic disorders. Tumor-educated blood 
platelets (TEPs) have emerged as promising biomarker sources for non-invasive 
detection of cancer, and it was demonstrated to discriminates patients with NSCLC 
from healthy individuals and patients with various non-cancerous inflammatory 
conditions [9, 10].Indeed, high platelet count (PLT) is associated with increased 
mortality in a variety of cancers, including malignant mesothelioma [11] , 
gynecological malignancies [12], and breast cancer [13]. In addition, 
platelet-to-lymphocyte ratio and mean platelet volume also add value in early 
diagnosis of lung cancer [14] and prognosis prediction [15, 16]. These findings, taken 
together, indicate that disordered platelet production may be connected to lung 
carcinogenesis. However, due to potential unmeasured confounders in observational 
studies, the association between PLT and lung cancer risk remains unclear.  
 
Mendelian Randomization (MR) is based on the principle that an individual's genotype 
is randomized at conception[17] and utilizes genetic variants as instrumental variables 
(IV) for the association between phenotypic exposures and outcomes to eliminate 
bias due to unmeasured confounders. Genetic variants used as instrumental 
variables should meet the following assumptions: (1) genetic variants are associated 
with exposure, (2) genetic variants affect outcome only via the exposure, and (3) 
genetic variants are not associated with any confounders of the exposure–outcome 
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association.[18] By finding a genetic marker that satisfies instrumental variable 
assumptions, Mendelian randomization analysis has been broadly used to estimate 
unconfounded associations between exposure and outcome [19], such as the effect of 
higher adult height on escalated cancer risk [20-24]. 
 
In this study, we performed summary data-based Mendelian randomization (SMR) [25] 
analysis which is the extension of two sample Mendelian randomization, using 
curated platelet count-related SNPs as instrumental variables to evaluate the 
association between platelet count and lung cancer risk by using summary statistics 
from recent large scale genome-wide association studies (GWAS). 
 
Materials and Methods 
Data source and study population 
Mendelian Randomization analysis was conducted to estimate the effect of platelet 
count (X) on risk of lung cancer (Y) using genetic variants (G) as instrumental 
variables.[26] According to the MR analysis diagram described in Figure 1, we used 
coefficients of genetic variants on platelet count (bXG) and their standard errors (SEXG) 
from the recently published study of Gieger et al., which pooled 23 studies and 
included approximately 48,666 individuals of European descent [27]. 
 
The 54 genetic variants were identified that were associated with PLT (Table S1). One 
of the key assumptions underlying Mendelian Randomization is that the genetic 
variants (SNPs) used as instrumental variables are only related to the outcome of 
interest through the exposure variable under study. No pleiotropic pathways should 
exist from platelet-related SNPs to lung cancers through intermediates other than 
platelet count. Thus, six genetic variants (rs17030845, rs6141, rs3792366, rs210134, 
rs708382, and rs6065) where further selected as qualified instrumental variables that 
have prior functional knowledge supporting their association with platelets and no 
apparent link to cancer through intermediates other than platelets. By the way, the 
SNP rs6141 in THPO narrowly misses the level required for nominal significance 
(P<5×10-8) with P=6.18×10-8 in Europeans, but shows genome-wide significance in 
Japanese [28] . Therefore, it is still included serving as instrument variable for platelet 
count. 
 
Coefficients (βYG) and corresponding standard errors (SEYG) of the association 
between genetic variants and lung cancer risk were obtained from meta-analysis of 
existing Oncoarray and TRICL GWAS studies, which were detailed previously [29]. 
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Briefly, overall non-small cell lung cancer (NSCLC) samples were composed from 
Oncoarray and TRICL GWASs, including 29,266 cases and 56,450 controls, and 
subgroup analyses were performed for 11,273 adenocarcinoma (AC), 7,426 
squamous cell carcinoma (SqCC), and 2,664 small cell lung cancer (SCLC) cases 
(Table S2).  
 
Mendelian Randomization (MR) analysis 
Mendelian Randomization analysis with multiple instrumental variables was 
performed using an inverse-variance weighted (IVW) method combining the effect of 
genetic variants by weighted score. This score was used as an instrumental variable 
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In which N = 6 represents the number of instrumental variables included, and bYX_IVW 
and SEYX_IVW represent the effect of platelet count on lung cancer risk in log(OR) scale 
and its corresponding standard error. Associations of platelet count on risk of overall 
NSCLC and individual subtypes were analyzed. Results are presented as OR for lung 
cancer risk per 100×109/L increment of platelet count. 
 
Additionally, penalized IVW, robust IVW, MR-Egger, penalized MR-Egger, and robust 
MR-Egger methods were used for sensitivity analyses to evaluate robustness of the 
findings [30]. Step forward modeling was used to add an optimal instrumental variable 
each time from the left 48 SNPs, adding to the 6 curated SNPs for multiple 
instrumental variable analysis, until there was no improvement of statistical 
significance (P-value) for the test of causal effect. The modeling process was 
terminated when no added SNP increased -log10 (P-value) by 20% or 10%. Besides, 
MR analysis with a single IV (one SNP at a time ) was performed as supplementary. 
Effect of PLT on Lung cancer risk [bYX in log odds ratio (OR) scale] and its standard 
error (SEYX) were estimated as follows [31]: 
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All analyses were performed using R Software Version 3.3.1 (The R Foundation). All 
tests were two-sided, and P ≤ 0.05 was considered statistically significant unless 
stated otherwise.  
 
Results 
Among 48,666 Europeans, 54 SNPs were quantitatively associated with platelet count 
with P ≤ 5×10-8 (Table S1) [27]. Associations of those 54 SNPs with risk of lung cancer 
were analyzed among 29,266 cases and 56,450 controls from OncoArray and 
previous GWAS studies. Demographics and study descriptions were detailed 
previously [29] and are briefly listed in Table S2 as well. Summarized association 
results of SNPs and lung cancer risk are listed in Table S3. According to instrumental 
variable assumptions that had evidence only related to platelets, six SNPs which are 
relatively independent and situated in different chromosomes were selected for MR 
analysis (Table 1), and 48 SNPs were excluded (Table S4).  
 
In multiple IV analysis combining all six relatively independent SNPs situated in 
different chromosomes, a significant association between PLT and overall NSCLC risk 
is revealed, showing that each 100×109/L increment of PLT was associated with a 62% 
increase in NSCLC risk (95%CI, 1.15–2.27; P = 0.005) (Figure 2A and Figure 3A). In 
addition, five different methods of sensitivity analysis, including penalized IVW, robust 
IVW, MR-Egger, penalized MR-Egger, and robust MR-Egger, retained this association 
(Table 2). In NSCLC subtype analysis, it failed to detected significant associations 
between PLT and the risk of lung Adenocarcinoma (AC) (OR, 1.51; 95%CI, 0.92–2.48; 
P = 0.11) (Figure 2B and Figure 3B) and squamous cells carcinomas (SqCC) (OR, 
1.59; 95%CI, 0.86–2.92; P = 0.14) (Figure 2C and Figure 3C). On the other hand, it is 
suggested that PLT is significantly associated with the risk of small cell lung cancer 
(SCLC) (OR, 3.00; 95%CI, 1.27–7.06; P = 0.01) (Figure 2D and Figure 3D). The 
results of single IV are presented in supplementary (Table S5). No correction was 
conducted for them because a single weak instrument will have lower power to reject 
the null hypothesis [32]. 
 
We also performed a step forward modeling strategy to include more instrumental 
SNPs in the multiple instrumental variable model. Including more SNPs as 
instrumental variables yielded similar, yet more significant, causal estimates (Table S6 
and Figure S1).  
 
Discussion 
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This Mendelian randomization study suggests that each 100×109/L increment in 
platelets results in a 62% increased risk of non-small cell lung cancer and, notably, a 
200% increased risk of small cell lung cancer. However, this study failed to show 
evidence of a relationship between PLT and risk of AC and SqCC, probably resulting 
from insufficient sample size. As comparing with SCLC, the effect size of PLT on AC 
and SqCC are weaker, larger sample size is needed [33].  
 
Platelets have been studied for decades as an important regulator of inflammation 
and thrombosis [34], which are broadly interrelated with human carcinogenesis [13]. 
Platelets are also recognized as a stimulator of proangiogenic factors [13] and a major 
source of vascular endothelial growth factor (VEGF) [35], platelet-derived growth 
factor (PDGF) [36, 37], and basic fibroblast growth factor (bFGF) [37], which act as 
promoters of tumor growth in lung [38-44]. New evidence suggests that platelets are 
relevant to defensive, physiological immune responses of the lungs and to 
inflammatory lung diseases [45]. Thus, higher platelet count has a potential biological 
connection to increased risk of lung cancer. Interestingly, p-selectin, an important 
adhesion molecule expressed on the surface of activated platelets, is more highly 
expressed in lung adenocarcinomas and squamous cell carcinomas than in healthy 
populations [46]. These results indicate a considerable role of platelets in lung 
carcinogenesis.  
 
Intriguingly, a recent study indicates that cancer cells depend on platelets to avoid 
anoikis and succeed in metastasis [47]. Platelets induce resistance to anoikis in vitro 
and are critical for metastasis in vivo by activating RhoA-MYPT1-PP1-mediated YAP1 
dephosphorylation and promoting its nuclear translocation to inhibit apoptosis. 
However, the unknown underlying mechanism warrants future well-designed 
functional experiments to clarify the role of platelets in these cellular processes. 
 
In addition, anti-platelet agents, such as purinergic antagonists, are used clinically 
because they affect inflammatory pathways [48]. Recent publications demonstrate 
that platelets suppress T-cell responses against tumors through production and 
activation of immunosuppressive factors. These results suggest the use of a 
combination of immunotherapy and platelet inhibitors, such as aspirin [49, 50] and 
clopidogrel, as a therapeutic strategy against cancer [51, 52]. Therefore, it is possible 
that anti-platelet therapy could reduce lung cancer risk.  
 
However, we acknowledge some limitations in our study. First, some associations 
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between genetic instrumental variables and phenotype (platelet count) were 
insufficient and thus may result in a "weak instrument" phenomenon [53]. Second, in 
some scenarios, inconsistent results were observed between inverse-variance 
weighted and MR-Egger (or regular and penalized/robust) models. This phenomenon 
indicates that genetic variants probably have horizontal pleiotropy, and thus MR 
assumptions are likely violated [54]. Moreover, there is heterogeneity across results 
incorporating different SNP sets as instrumental variables, which indicates that the 
instrumental variable should be curated carefully before Mendelian randomization 
analysis. In this study, all platelet count-related SNPs were curated, and six were 
retained to better satisfy MR assumptions. Third, a linear association was assumed 
between PLT and lung cancer risk. However, the shape could be non-linear and thus 
warrants further study incorporating individual-level data. Fourth, we only evaluated 
platelet count as a potential causal factor, whereas platelet function plays a 
comparable causal role in this pathway. More detailed platelet information should be 
measured in future studies, including immature platelet fractions and function. In 
addition, we assumed that study populations used for the genetic instrument for 
platelet count and for risk of lung cancer were representative of the same general 
Caucasian population, which may not be true. Therefore, additional functional studies 
are needed to further evaluate the mechanisms that underlie associations between 
platelets and lung cancer risk.  
 
Nonetheless, our ﬁndings do suggest a role of platelet count in risk of lung cancer. 
The results provide a better understanding of lung cancer etiology and evidence for a 
possible role of anti-platelet interventions in lung cancer prevention. 
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EAF (%) Function b (95% CI) P 
rs17030845 2: 43687879 THADA C T 09.65 intron –3.58 (–4.67, –2.49) 1.27×10–10 
rs6141 3: 184090266 THPO T C 47.39 3’ UTR –2.47 (–3.36, –1.57) 6.18×10–8 
rs3792366 3: 122839876 PDIA5 A G 38.68 intron 2.153 (1.44, 2.87) 3.60×10–9 
rs210134 6: 33540209 BAK1 G A 29.29 
500bp 
downstream 
–4.96 (–5.73, –4.18) 7.11×10–36 
rs708382 17: 42442344 FAM171A2-ITGA2B T C 39.66 2kb upstream –2.44 (–3.28, –1.59) 1.51×10–8 
rs6065 17: 4836381 GP1BA C T 08.53 missense 4.19 (2.96, 5.43) 2.92×10–11 
EAF, effect allele frequency; UTR, untranslated region 
  
on April 10, 2019. © 2019 American Association for Cancer Research. cebp.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on January 30, 2019; DOI: 10.1158/1055-9965.EPI-18-0356 
 22 
Table 2. Association between platelet count and risk of lung cancer using multiple IV analysis 
 
SNP 
Overall NSCLC AC SqCC SCLC 
OR (95%CI) P OR (95%CI) P OR (95%CI) P OR (95%CI) P 
IVW 1.62 (1.15, 2.27) 0.005 1.51 (0.92, 2.48) 0.11 1.59 (0.86, 2.92) 0.14 3.00 (1.27, 7.06) 0.01 
Penalized IVW 1.62 (1.15, 2.27) 0.005 1.51 (0.92, 2.48) 0.11 1.59 (0.86, 2.92) 0.14 3.00 (1.27, 7.06) 0.01 
Robust IVW 1.63 (1.26, 2.11) <0.001 1.51 (0.90, 2.53) 0.12 1.54 (0.93, 2.56) 0.09 3.30 (1.52, 7.15) 0.003 
MR-Egger 3.25 (1.16, 9.11) 0.03 6.06 (1.45, 25.27) 0.01 1.75 (0.22, 13.84) 0.59 3.29 (0.24, 45.11) 0.37 
Penalized MR-Egger 3.25 (1.16, 9.11) 0.03 6.06 (1.45, 25.27) 0.01 1.75 (0.22, 13.84) 0.59 3.29 (0.24, 45.11) 0.37 
Robust MR-Egger 3.23 (1.80, 5.78) <0.001 5.88 (2.74, 12.61) <0.001 1.70 (0.48, 6.08) 0.41 3.56 (1.25, 10.14) 0.02 
OR, odds ratio of platelet count (PLT) on lung cancer risk per 100×109/L increment of PLT; NSCLC, non-small cell lung cancer; AC, 
adenocarcinoma; SqCC, squamous cell carcinoma; SCLC, small-cell carcinoma; IVW, inverse-variance weighted.  
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Figure Legends. 
Figure 1. Diagram of Mendelian randomization (MR) analysis. MR aims to estimate 
the unbiased causal relationship between PLT and lung cancer risk by incorporating 
genetic variants as instrumental variables (IVs). Dashed line represents the 
association between instrumental variable (SNP) and outcome (risk of lung cancer), 
denoted using bYG in log(odds ratio) scale and its standard error (SEYG), which were 
obtained from GWAS. Estimates of quantitative trait loci relationship between SNP 
and phenotype (platelet count) were obtained from a recently published article, which 
were described by bXG and SEXG. Lung cancer risk was assessed for non-small cell 
lung cancer (NSCLC), adenocarcinoma (AC), squamous cell carcinoma (SqCC), and 
small cell carcinoma (SCLC). 
 
Figure 2. Causal associations between platelet count and lung cancer risk. Forest 
plots of causal associations between platelet count (PLT) and risk of lung cancer 
using Mendelian randomization (MR) analysis incorporating different genetic variants 
as instrumental variables (IVs). Associations of PLT with risk of (A) non-small cell lung 
cancer (NSCLC), (B) adenocarcinoma (AC), (C) squamous cell carcinoma (SqCC), 
and (D) small-cell lung cancer (SCLC) were analyzed based on single IV or multiple 
IVs using inverse-variance weighted (IVW) analysis. 
 
Figure 3. Assocations between SNPs and lung cancer risk. Scatter plots displaying 
estimates of the association between each SNP and risk of lung cancer against 
quantitative relationship of each SNP on platelet count (PLT) for (A) non-small cell 
lung cancer (NSCLC), (B) adenocarcinoma (AC), (C) squamous cell carcinoma 
(SqCC), and (D) small cell lung cancer (SCLC). Slope of the blue dashed line through 
the plot represents inverse-variance weighted (IVW) regression estimate for the 
causal effect of PLT on lung cancer risk. 
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